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SUMMARY 
C-peptide is a protein secreted by the pancreatic beta cells in equimolar quantities with 
insulin, following the cleavage of proinsulin into insulin. Measurement of C-peptide is used 
as a surrogate marker of endogenous insulin secretory capacity. Assessing C-peptide levels 
can be useful in classifying the sub-type of diabetes as well as assessing potential treatment 
choices in the management of diabetes. 
Standard measures of C-peptide involve blood samples collected either fasted or, most 
often, after a fixed stimulus (such as oral glucose, mixed meal or IV glucagon).  Despite the 
established clinical utility of blood C-peptide measurement, its widespread use is limited. In 
many instances this is due to perceived practical restrictions associated with sample 
collection.  
Urine C-peptide measurement is an attractive non-invasive alternative to blood measures of 
beta-cell function. Urine C-peptide creatinine ratio measured in a single post stimulated 
sample has been shown to be a robust, reproducible measure of endogenous C-peptide 
which is stable for three days at room temperature when collected in boric acid.  Modern 
high sensitivity immunoassay technologies have facilitated measurement of C-peptide down 
to single picomolar concentrations.  
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INTRODUCTION 
Insulin secretory capacity can be assessed by measuring C-peptide, a protein secreted by 
the pancreas in equimolar quantities with insulin, following the enzymatic cleavage of 
proinsulin into insulin (see figure 1). C-peptide is an attractive surrogate marker  of insulin 
secretion because it can be used in patients administered exogenous insulin therapy and it 
is more reflective of insulin secretion than insulin itself, due to the variable clearance of 
insulin by the liver before it reaches the peripheral circulation 1. C-peptide metabolism largely 
occurs in the kidney through glomerular filtration and uptake by tubular cells from peritubular 
capillaries, with 5-10% normally excreted in the urine. This is in contrast to insulin, 50% of 
which is metabolised and extracted in the liver. The total quantity of C-peptide excreted in 
the urine per day represents 5 % of pancreatic secretion, compared to only 0.1 % of 
secreted insulin 2. Consequently, despite equimolar secretion, C-peptide has a longer half-
life of approximately 30 minutes compared with only 6 minutes for insulin and occurs in the 




Figure 1: Diagram of pro-insulin demonstrating the A chain and B chain of insulin and the connecting peptide (C-
peptide), figure adapted from Stoyet al 2007 
5
. During the biosynthesis of insulin, the C peptide promotes proper 
protein folding and disulfide bonds between the A and B chains. 
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C-peptide and differentiating subtypes of diabetes 
The assessment of endogenous C-peptide production in diabetes can be useful in 
classifying the sub-type of diabetes. In a patient with young onset diabetes persistent C-
peptide production may reflect the honeymoon period of a patient with Type 1 diabetes, but 
also enduring C-peptide can be a feature of other types of diabetes including Type 2 
diabetes where levels are typically high. 
There is extensive evidence that C-peptide can be used to differentiate between the 
classification of Type 1 diabetes and Type 2 diabetes 
6-10. C-peptide is a good candidate 
biomarker to differentiate patients with Maturity Onset Diabetes of the Young (MODY) from 
Type 1 diabetes. Type 1 diabetes is characterised by autoimmune destruction of beta-cells 
and ultimately results in absolute insulin deficiency, usually within 5 years of diagnosis 
11
. In 
patients with a genetic diagnosis of MODY, beta cell function is typically maintained with 
time despite a reduction in insulin secretion and progressive hyperglycaemia 
12.The ISPAD 
Clinical Practise Consensus Guidelines ‘Compendium on the diagnosis and management of 
monogenic diabetes in children and adolescents’ published in 2009 
13  and best practice 
guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young, 
published in 2008 
14
 both acknowledge that persistent C-peptide production can be used to 
identify patients likely to harbour a mutation in a MODY gene. Both guidelines suggest after 
the initial honeymoon period in patients with suspected Type 1 diabetes (typically >5 years) 
a blood C-peptide level of >200 pmol/L suggests a possible diagnosis of MODY.  These 
guidelines are supported by recent reports which have shown that a urine C-peptide can be 
used to discriminate Type 1 diabetes from MODY with a high sensitivity and specificity 15,16  
Measurement of C-peptide 
Blood C-peptide 
Standard measures of C-peptide involve blood samples collected either fasted or, most 
often, after a fixed stimulus (such as oral glucose, mixed meal or IV glucagon) 1,17,18. Despite 
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the established clinical utility of blood C-peptide measurement, its widespread use is limited. 
In many instances this is due to practical restrictions associated with sample collection. Both 
insulin and C-peptide concentrations are widely considered to be unstable and require 
specific pre-analytical handling procedures with many laboratory providers stipulating the 
need for blood samples to be rapidly centrifuged after collection on ice and the serum or 
plasma immediately frozen following separation from cells  1,19. However, these strict 
handling protocols may not be necessary as there is evidence that C-peptide is stable for up 
to 24 hours on whole blood if collected into EDTA preservative 20. 
Urine C-peptide 
There is a body of evidence that suggests 24 hour urine C-peptide (UCP) levels provide an 
accurate means of assessing beta cell-secretory capacity and correlate with both fasting and 
stimulated serum insulin and C-peptide  2,8,21,22. 
However, the cumbersome nature and difficulties in obtaining an accurate and complete 24 
hour urine collection has limited the utility of this test 
23-25. Urine samples collected over a 
period of four hours and single post stimulated UCP have been shown to be significantly 
correlated with serum insulin and serum C-peptide in non-diabetic subjects 
26
, and in insulin 
treated diabetic patients
7
. Correcting for creatinine adjusts urine C-peptide concentration for 
variation in urine concentration and enables the use of ‘spot’ urine samples in place of 24-h 
urine collection. Urinary C-peptide when collected in boric acid is stable for up to three days 
at room temperature making it possible to be collected remotely from the processing 
laboratory and even posted into the laboratory by patients 27. Urine C-peptide creatinine ratio 
correlates strongly with blood C-peptide and has been validated in non-diabetics, type 1 
diabetes, type 2 diabetes, adults and children 15,16,28-35.  
C-peptide assays 
Early assays for C–peptide were radioimmunoassays and suffered from poor analytical 
sensitivity and specificity and are time-consuming to perform (and therefore expensive) 
1,36,37. The introduction of non-isotopic assays (chemiluminescence, fluorescence, etc.) that 
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utilise monoclonal antibodies has improved analytical sensitivity, specificity, reproducibility 
and reduced assay costs (to approximately £10).  These technologies are also amenable to 
automation, allowing these assays to be incorporated into large high throughput clinical 
analysers. 
MATERIALS 
 Urine collected into boric acid container. For interpretation of beta-cell reserve, the 
sample should be a stimulated sample, collected 2 hours after the biggest meal of 
the day (see Methods section on patient preparation) 
 Roche Modular Analytics E170 immunoassay analyser (Roche Diagnostics, 
Mannheim, Germany). 
 C-peptide calibration material: Roche C-peptide Calibration Set (Roche Diagnostics, 
Mannheim, Germany) 
 C-peptide quality control material:  Elecsys Precicontrol Multianalyte (Roche 
Diagnostics, Mannheim, Germany)  
 Roche C-peptide chemiluminescence assay kit (Roche Diagnostics, Mannheim, 
Germany) 
 Diluent used for C-peptide assay (Equine serum albumin): Roche Diluent MultiAssay 
(Roche Diagnostics, Mannheim, Germany) 
 Roche Creatinine modified Jaffe  assay kit (Roche Diagnostics, Mannheim, 
Germany) 
 Creatinine calibration material: Roche Calibrator for automated systems (Roche 
Diagnostics, Mannheim, Germany) 
 Creatinine QC material: Randox assayed urine control level 2 & 3 (Randox UK, Co. 
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METHODS 
Patient preparation: To assess the maximum endogenous C-peptide response, a 
stimulated urine sample should be collected.  Patients should be briefed with the following 
information before sample collection: 
1. Pass urine just before the biggest meal of the day and discard. 
2. Eat the meal as usual with a glass or more of water. 
3. Do not eat anything else for the next 2 hours unless you have a hypoglycaemic 
episode, in which case you should do this test on another day. You can drink water 
freely throughout the duration of the collection. 
4. 2 hours after this meal, collect urine and send for analysis.  
 
Sample storage and stability 
Urine C-peptide concentration is unchanged at room temperature for 24 h and at 4 °C for 72 
h even in the absence of preservative.  
Urine C-peptide collected in boric acid is stable at room temperature for 72 hours. Urine C-
peptide remained stable after 7 freeze-thaw cycles but decreased with freezer storage time 
and dropped to 82%-84% of baseline by 90 days at -200C 27. 
 
Roche assay used to measure C-peptide in urine 
C-peptide analysis is performed on the high throughput Roche Modular Analytics E170 
immunoassay analyser (Roche Diagnostics, Mannheim, Germany). The assay is a 
heterogeneous sandwich immunoassay. Urine is diluted 10-fold with Multi Assay Diluent . 
One biotinylated anti-C-peptide specific monoclonal mouse antibody and a second 
monoclonal antibody to C-peptide labelled with a ruthenium complex, react with C-peptide in 
20μL of diluted urine sample to form an antigen-antibody-antigen sandwich complex. 
Separation is achieved via interaction of biotin and streptavidin attachment to paramagnetic 
microparticles (solid phase). The detection system employs electrochemiluminescence with 
ruthenium trisbipyridyl as the label. 
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Electrochemiluminescence occurs at 620 nm and readings are taken by the photomultiplier 
tube . The intensity of light signal is proportional to the concentration of C-peptide in the 
serum. All urine samples were pre-diluted 1:10 with equine serum albumin (diluent 
multianalyte, Roche Diagnostics, Mannheim, Germany). (See Note 2).The analysis time is 
18 minutes per specimen. The E170 is able to analyse 170 samples per hour. 
The assay was calibrated using Roche C-peptide CalSet calibration material (Roche 
Diagnostics, Mannheim, Germany), traceable to WHO International Reference Reagent 
(IRR) for C-peptide of human insulin for immunoassay (IRR code 84/510) 
38
. Quality Control 




The measuring range of the urine C-peptide assay is from 0.03 – 133 nmol/L. 
There is approximately 30% cross-reactivity with pro-insulin (see Note 3) 
 
Roche assay used to measure creatinine in urine 
Creatinine is analysed on the Roche P modular analyser (Roche Diagnostics, Mannheim, 
Germany). The test principle is a kinetic colorimetric assay based on the Jaffé reaction as 
described by Popper et al., 1937 and modified by Bartels et al. in 1972 
39. 
In alkaline solution, creatinine forms a yellow-orange complex with picrate. The colour 
intensity is directly proportional to the concentration of creatinine in the urine sample and is 
measured photometrically at 500 nm. 
The assay was calibrated on each day of analysis using a two point calibration with Roche 
Calibrator for Automated Systems  calibration material, traceable to Isotope Dilution-Mass 
Spectrometry (ID-MS) reference method. Quality Control was performed on each day of 
analysis using Randox assayed urine control level 2 & 3 
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Measuring range, units 
The measuring range for creatinine in urine is 0.36-57.5 mmol/L .Samples that have a 
creatinine concentration greater than this may be diluted 1:2 via the automatic re-run 
function, using saline as a diluent. 
 
Interpretation of results 
UCPCR is restricted to use in patients on insulin treatment to assess endogenous insulin 
secretion.  Its role in patients not on insulin treatment is limited. 
If the of UCPCR result is not in keeping with other clinical finding then we would recommend 
repeating the test especially if it is unexpectedly low.  Patients tipping out boric acid 
preservative from urine collection tube, in a sample taking more than 3 days to reach the 
laboratory can result in artificially low results 27.  We are not aware of any reason or 
experience a falsely high value. 
Most of the studies have been performed in patients with normal renal function (eGFR>60 
mL/min/1.73 m2) but it has been validated in patients with Type 2 diabetes with moderate 
renal impairment (eGFR 30-60 mL/min/1.73 m2    30.  The test is unlikely to be appropriate in 
patients with severe renal impairment. 
 
What values are expected in the different subtypes? 
The UCPCR result is best measured on a post prandial sample taken approximately two 
hours after a meal stimulus.  The interpretation depends on the specific clinical scenario i.e. 
type of diabetes and treatment. Median and 5-95th percentile UCPCR values for non-diabetic 
controls,  long standing Type 1 diabetes(> 5 years), Type 1 diabetes in the first five years 
after diagnosis, Type 2 diabetes (OHA and insulin treated) and patients with a genetic 










  Males  Females  
  UCPCR (nmol/mmol) UCPCR (nmol/mmol) 
Patient Group 5th 25th 50th 75th 95th 5th 25th 50th 75th 95th 
Controls 0.58 1.64 2.84 7.04 10.39 1.82 3 4.04 6.99 10.37 
Type 1 
Diabetes 
             
> 5 years 
duration 
<0.02 <0.02 0.02 0.02 0.02 0.00 0.00 0.02 0.04 0.04 
<5 years 
duration 
0.02 0.55 1.24 1.79 5.78 0.02 0.55 1.24 1.79 5.78 
Type 2 
Diabetes 
             
On OHA 0.35 1.6 2.87 4.08 7.80 1.28 2.34 3.85 5.68 9.43 
On insulin 0.08 0.5 1.3 2.36 5.65 0.15 0.6 1.4 2.8 6.12 
HNF 1/4A              
On OHA 0.54 1.36 1.84 2.80 6.10 0.54 1.23 2.93 4.04 10.02 
On Insulin 0.10 0.54 1.12 1.72 3.47 0.10 0.54 1.12 1.72 3.47 
 
Table 1: UCPCR ranges in diabetes subtypes and controls (unpublished data). 
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NOTES 
1- Agreement of urine C-peptide measurements in different commercially 
available assays - There is poor comparability between commercial and in-house C-
peptide assays making transferability of C-peptides values/cut-offs from research to 
clinical practice problematic 
40-42
. International working groups (in the USA and 
Europe) are currently addressing the widely disparate values between analytical 
methods for both C-peptide and insulin 
40,42,43
. The groups are combining efforts to 
improve standardisation with the aim of establishing a complete reference 
measurement system and certified primary reference materials based on pure 
biosynthetic insulin and C-peptide
43
.  
2- Using other diluents in the Roche C-peptide assay- C-peptide is approximately 20 
fold more concentrated in urine samples and therefore require dilution before 
analysis. We have found that the diluent must be proteinaceous (e.g. equine serum 
albumin) in order to achieve both a concentration and matrix that will generate a 
comparable and reproducible result. This has been shown for three different platforms 
measuring C-peptide (Roche, Immunlite and Centaur).(*unpublished data derived at 
the Blood Sciences Dept, RD&E) 
3- Cross reactivity of the Roche assay with proinsulin- Proinsulin does cross react 
with the Roche assay (30% cross reactivity) despite the fact that the assay utilises 
two site monoclonal antibodies. However, proinsulin and split products exist in much 
lower concentrations than C-peptide in serum (< 2% in non-diabetics) and are 
therefore of little clinical significance except for in rare conditions such as insulinoma 
44.  In addition, the total quantity of C-peptide excreted in the urine per day represents 
5-10 % of pancreatic secretion, compared to only 0.05 % of secreted proinsulin (2-3 
times lower than insulin of which only 0.1% is excreted into the urine 45). With only 
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30% cross reactivity in the Roche assay the contribution of proinsulin to urine C-
peptide measurement would be negligible. 
4- Making a diagnosis in insulin treated patients- The principal role of urinary C-
peptide is to identify insulin insufficiency, a feature of long term Type 1 diabetes, in 
insulin treated patients. We have found that > 95% Type 1 diabetes (> 5 year 
duration) have a UCPCR value < 0.2 nmol/mmol. 
o Type 1 v MODY 
A cut-off UCPCR of 0.2 nmol/mmol differentiates HNF1A/4A MODY from 
Type 1 diabetes with a sensitivity of 97% and specificity of 96% (ROC 0.98)15.  
o Type 1 v Type 2 
A cut-off of 0.2 nmol/mmol differentiates Type 2 diabetes from Type 1 
diabetes with 94 % sensitivity and 94% specificity (ROC AUC  0.94). 
5- Monitoring the honeymoon period in Type 1 diabetes 
In patients with Type 1 diabetes it is possible to measure the extent to which they are 
progressing through the honeymoon phase.  UCPCR is highly correlated with the 
serum C peptide in a formal mixed tolerance test 32 
6- Assessing in insulin treated Type 2 diabetes the extent of endogenous insulin 
secretion 
Endogenous insulin secretion can be measured in Type 2 diabetes.  UCPCR is 
highly correlated with the serum C-peptide in a formal mixed tolerance test 29.  
Patients with a high endogenous secretion >75th centile (table 1) are likely be those 
that benefit most from metformin and other oral agents.  Patients with low 
endogenous insulin secretion < 25th centile and particularly if UCPCR <0.02 
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